tetano
Editor, Senior Moderator
Intern Med
. 2023 Mar 1.
doi: 10.2169/internalmedicine.0394-22. Online ahead of print.
Anti-myelin Oligodendrocyte Glycoprotein Antibody-positive Myelitis after Coronavirus Disease 2019
Kenji Uchino[SUP] 1 [/SUP], Kaima Soga[SUP] 1 [/SUP], Kensuke Shinohara[SUP] 1 [/SUP], Takeshi Imai[SUP] 2 [/SUP], Iori Motohashi[SUP] 3 [/SUP], Hirohisa Okuma[SUP] 1 [/SUP], Yoshihisa Yamano[SUP] 2 [/SUP]
Affiliations
Abstract
We herein report a case of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-related myelitis caused by coronavirus disease (COVID-19) infection in 2021. A 22-year-old man with no history of any related illness contracted COVID-19. Eight days later, he developed bladder problems, paraplegia and sensory disturbances. Cervical spinal cord magnetic resonance imaging revealed extensive hyperintensity at T2 and spinal cord lesions extending from C4 to Th1. The patient was diagnosed with transverse myelitis and started on intravenous methylprednisolone, plasma exchange and intravenous immunoglobulin therapy. The symptoms improved only after intravenous methylprednisolone therapy. Anti-MOG antibodies were found in his serum and cerebrospinal fluid during routine screening. As this observation is unusual and could cause serious health problems, we wonder if COVID-19 triggered this autoimmune response.
Keywords: COVID-19; Oligodendrocyte myelin glycoprotein; autoimmune; prednisolone; transverse myelitis.
. 2023 Mar 1.
doi: 10.2169/internalmedicine.0394-22. Online ahead of print.
Anti-myelin Oligodendrocyte Glycoprotein Antibody-positive Myelitis after Coronavirus Disease 2019
Kenji Uchino[SUP] 1 [/SUP], Kaima Soga[SUP] 1 [/SUP], Kensuke Shinohara[SUP] 1 [/SUP], Takeshi Imai[SUP] 2 [/SUP], Iori Motohashi[SUP] 3 [/SUP], Hirohisa Okuma[SUP] 1 [/SUP], Yoshihisa Yamano[SUP] 2 [/SUP]
Affiliations
- PMID: 36858516
- DOI: 10.2169/internalmedicine.0394-22
Abstract
We herein report a case of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-related myelitis caused by coronavirus disease (COVID-19) infection in 2021. A 22-year-old man with no history of any related illness contracted COVID-19. Eight days later, he developed bladder problems, paraplegia and sensory disturbances. Cervical spinal cord magnetic resonance imaging revealed extensive hyperintensity at T2 and spinal cord lesions extending from C4 to Th1. The patient was diagnosed with transverse myelitis and started on intravenous methylprednisolone, plasma exchange and intravenous immunoglobulin therapy. The symptoms improved only after intravenous methylprednisolone therapy. Anti-MOG antibodies were found in his serum and cerebrospinal fluid during routine screening. As this observation is unusual and could cause serious health problems, we wonder if COVID-19 triggered this autoimmune response.
Keywords: COVID-19; Oligodendrocyte myelin glycoprotein; autoimmune; prednisolone; transverse myelitis.